Compare Brown-Forman Corporation Class B (BF.B) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Novo Nordisk A/S — how do they compare? Brown-Forman Corporation Class B trades at $27.84, while Novo Nordisk A/S trades at $46.02 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Brown-Forman Corporation Class B pays none, and Brown-Forman Corporation Class B is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| BF.B | NVO | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $63.98 |
52-Week Low | $22.80 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $28.19, down 1.16% for the day, with technical indicators showing a bullish trend supported by moving averages. The stock has demonstrated strong earnings performance, beating expectations in three of the last four quarters. Analyst sentiment is mixed with a 25% buy rating amid limited recent news coverage.
The outlook remains cautiously optimistic given recent earnings strength, though the divided analyst consensus and lack of current financial metrics present valuation challenges. Key risks include execution consistency and market volatility, while institutional positioning will be critical for sustained momentum.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
